Douglass Winthrop Advisors LLC Acquires 545 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Douglass Winthrop Advisors LLC increased its stake in Thermo Fisher Scientific by 2.2%, now owning 25,878 shares valued at approximately $12.88 million.
• Thermo Fisher's shares recently traded up by 3.4%, with a current price of $500.24 and a market cap of $188.89 billion.
• Insiders, including the CEO and an EVP, have recently sold shares, indicating a decrease in their positions amidst ongoing investor interest.

Douglass Winthrop Advisors LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,878 shares of the medical research company's stock after purchasing an additional 545 shares during the period. Douglass Winthrop Advisors LLC's holdings in Thermo Fisher Scientific were worth $12,877,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $25,000. Ameriflex Group Inc. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. Keystone Global Partners LLC purchased a new stake in Thermo Fisher Scientific during the 1st quarter valued at $31,000. IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific in the 1st quarter worth $35,000. Finally, Navigoe LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $37,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on TMO. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 10th. Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Argus cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. Finally, Evercore ISI lowered their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,896 shares of company stock worth $13,603,438. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded down $0.01 on Wednesday, reaching $488.47. 1,286,715 shares of the company's stock traded hands, compared to its average volume of 2,460,395. The firm has a market cap of $184.45 billion, a PE ratio of 28.25, a P/E/G ratio of 2.62 and a beta of 0.74. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The stock has a 50-day simple moving average of $446.71 and a 200-day simple moving average of $455.47. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter last year, the business posted $5.37 earnings per share. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.